BioSpace News Archive

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”) today announces additional new clinical and biomarker results from its Phase 2a CLEAR MIND trial of its investigational product Lomecel-B™ for the treatment of mild Alzheimer’s disease.

Akebia Therapeutics today announced that John Butler , Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11th , 2024.

Pulse Biosciences, Inc. today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Evolus, Inc. announced it has entered into a definitive agreement with Symatese to be the exclusive distributor in the United Kingdom and Europe of four unique dermal fillers in late-stage development with anticipated regulatory clearances in second half of 2024 and commercialization under the brand name Estyme® fillers in 2025.

Colossal Biosciences, the breakthrough genetic engineering and de-extinction company, is pleased to announce the formation of the Tasmania Thylacine Advisory Committee.

858 Therapeutics is pleased to announce today that it has named Katherine Bell-McGuinn, M.D., Ph.D., as Chief Medical Officer.

Terran Biosciences, Inc. has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans. Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first.

Thermo Fisher Scientific Inc. today announced the launch of CorEvidence, a proprietary cloud-based data lake platform optimizing pharmacovigilance case processing and safety data management processes.

Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume subcutaneously injected inhibitor of complement component 5 (C5), in development for patients with complement-mediated diseases.

MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the “Company” or “MindBio”), Chief Executive Officer Justin Hanka provides end of year video update on two Phase 2 clinical trials currently underway using MB22001.